These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36595377)

  • 1. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
    Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
    Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
    Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
    Front Immunol; 2022; 13():796349. PubMed ID: 35242129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
    Nunes NS; Kanakry CG
    Front Immunol; 2019; 10():2668. PubMed ID: 31849930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.
    Oshrine B; Innamarato P; Branthoover H; Nagle L; Verdugo P; Pilon-Thomas S; Beatty M
    Transplant Cell Ther; 2022 Apr; 28(4):203.e1-203.e7. PubMed ID: 34995816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
    Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Gress RE; Kanakry CG
    J Clin Invest; 2019 Mar; 129(6):2357-2373. PubMed ID: 30913039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
    Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
    Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
    Patterson MT; Khan SM; Nunes NS; Fletcher RE; Bian J; Hadjis AD; Eckhaus MA; Mendu SK; de Paula Pohl A; Venzon DJ; Choo-Wosoba H; Ishii K; Qin H; Fry TJ; Cam M; Kanakry CG
    Blood; 2023 Feb; 141(6):659-672. PubMed ID: 36201744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.
    Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Kanakry CG
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):230-241. PubMed ID: 31586477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
    Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
    Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
    Nakamae H
    Int J Hematol; 2022 Oct; 116(4):465-481. PubMed ID: 35930118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade.
    Ikegawa S; Meguri Y; Kondo T; Sugiura H; Sando Y; Nakamura M; Iwamoto M; Maeda Y; Matsuoka KI
    Blood Adv; 2019 Dec; 3(23):4081-4094. PubMed ID: 31821459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early myeloid-derived suppressor cells (HLA-DR
    Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes.
    Wang Y; Chang YJ; Chen L; Xu LP; Bian ZL; Zhang XH; Yan CH; Liu KY; Huang XJ
    Oncoimmunology; 2017; 6(11):e1356152. PubMed ID: 29147612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
    Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
    Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide.
    Sligar C; Cuthbertson P; Miles NA; Adhikary SR; Elhage A; Zhang G; Alexander SI; Sluyter R; Watson D
    Immunol Cell Biol; 2023 Aug; 101(7):639-656. PubMed ID: 37191045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.
    Cuthbertson P; Button A; Sligar C; Elhage A; Vine KL; Watson D; Sluyter R
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.